|
| On-Demand Webinar: Clinical Adjudication Survey Results Revealed In a recent survey, 89% of clinical adjudication users agreed clinical adjudication provides value to clinical trials. Why? Because using unbiased experts to evaluate a drug or device against predetermined criteria helps determine patient safety and clinical efficacy. Join two experts for a discussion of these and other survey results to understand how they could impact your studies. View Now. |
AstraZeneca picks up new weapon in rare disease fight with Alnylam and Pfizer, paying $30M for rights to an early-phase asset Healthcare smashed venture funding records in 2021 despite poor market performance Merck's Keytruda scores key NICE sign-off for first-line NSCLC indication Medtronic recalls StealthStation neurosurgery navigation software, again Sanofi makes AI play, putting up $100M and billions in biobucks to form broad deal with Exscientia Kaufman Hall: Consumers may again be avoiding getting care as hospital margins remain depressed Regeneron hands over Evkeeza rights to Ultragenyx outside US, with an R&D asset also thrown in Cue Health to develop omicron-specific portable COVID test with BARDA backing Atea sticks it out with failed COVID-19 antiviral but also raids Merck's store room for hepatitis C drug CMS proposes Part D price concessions be applied at point-of-sale, new requirements for MA plans Merck, putting $150M on the table, doubles down on pledge to tackle maternal mortality and health inequities DOJ charges doctor with reusing single-use devices in $46M Medicare fraud scheme Featured Story | By Nick Paul Taylor AstraZeneca is stepping up its pursuit of a rare disease market targeted by Alnylam and Pfizer. Having entered the ATTR space through its takeover of Alexion, AstraZeneca is paying $30 million for worldwide rights to Neurimmune’s NI006 in its second deal in the indication in quick succession. read more |
| |
|---|
|
|
| Webinar: A Collaborative Approach to Complex Chemistry Wednesday, January 12, 2022 | 11am ET / 8am PT Complex therapeutics demand complex chemistry expertise. Discover how the right partner can help you overcome complex chemistry challenges through extensive experience, specialised technologies, and true scientific collaboration. Register now. |
Top Stories By Rebecca Torrence While the healthcare market slumped in 2021, venture fundraising soared to record highs, with $28.3 billion invested in the U.S., nearly doubling 2020's record—a pace that may not hold steady in the coming year. read more By Kevin Dunleavy On Friday, when England’s National Institute for Health and Care Excellence signed off on Merck’s megablockbuster Keytruda for another indication, it represented a key first-line breakthrough in the treatment of lung cancer—not just another in a long line of label expansions for the versatile drug. read more By Andrea Park Three years after launching a Class I recall of some of its StealthStation surgical navigation software, Medtronic has once again received the FDA’s most serious classification for yet another recall of the software, and for a very similar issue. read more By Nick Paul Taylor Sanofi is getting deeper into AI-driven R&D. After working with AI drug discovery shop Exscientia for five years, Sanofi has significantly expanded its relationship, putting up $100 million and $5.2 billion on the backend for the chance to work on up to 15 small molecules across oncology and immunology. read more By Robert King A new report from Kaufman Hall found that hospital volumes softened in November and estimates consumers could be putting off care again. read more By Ben Adams After nabbing U.S. and European approvals in the past year, Regeneron is shipping the sales and development rights to its ultrarare cholesterol drug Evkeeza over to rare disease specialist Ultragenyx. read more By Conor Hale The new cartridge-based, nasal swab test will be compatible with the company’s point-of-care reader. read more By Annalee Armstrong Atea Pharmaceuticals is still determined to get its COVID-19 antiviral through clinical trials, but without a partner to collaborate with, the biotech is also raiding Merck's storeroom to make a play in a different indication. read more By Robert King CMS wants Part D plans to apply price concessions they get from drugmakers to the point-of-sale to ensure maximum benefit for consumers, according to a major proposed rule. read more By Natalie Missakian Around the world, a woman dies every two minutes from pregnancy or childbirth complications—most of them preventable. Merck has spent the last decade trying to change that, and now it’s doubling down. read more By Andrea Park Days after landing a partial guilty verdict in disgraced Theranos CEO Elizabeth Holmes’ federal fraud trial, the U.S. Department of Justice’s crusade against healthcare scammers rages on. read more |
